UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 2, 2006

OR

TRANSITION REPORT

PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition

period from________to_______

COMMISSION FILE

NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235

East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip

code)

(212) 573-2323

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has

filed all reports required to be filed by Section 13 or 15(d) of the

Securities Exchange Act of 1934 during the preceding 12 months (or for such

shorter period that the registrant was required to file such reports) and (2)

has been subject to such filing requirements for the past 90 days.

YES X NO

Indicate by check mark whether the registrant is a large

accelerated filer, an accelerated filer, or a non-accelerated filer. See

definition of "accelerated filer and large accelerated filer" in

Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer X

Accelerated Filer Non-accelerated

filer

Indicate by check mark whether the registrant is a shell

company (as defined in Rule 12b-2 of the Exchange Act).

YES NO X

At July 31, 2006, 7,291,451,351 shares of the issuer's

voting common stock were outstanding.

FORM 10-Q

For the Quarter

Ended

July 2, 2006

Table

of Contents

PART I. FINANCIAL

INFORMATION

Page

Item 1.

Financial Statements:

Condensed

Consolidated Statements of Income for the three months and six months ended July 2,

2006 and July 3, 2005

Condensed

Consolidated Balance Sheets at July 2, 2006 and

December 31, 2005

Condensed Consolidated

Statements of Cash Flows for the six months ended July 2, 2006 and July 3,

2005

Notes to

Condensed Consolidated Financial Statements

Review Report

of Independent Registered Public Accounting Firm

23

Item 2.

Management's

Discussion and Analysis of Financial Condition and Results of Operations

24

Item 3.

Quantitative

and Qualitative Disclosures About Market Risk

52

Item 4.

Controls and

Procedures

52

PART II. OTHER

INFORMATION

Item 1.

Legal

Proceedings

53

Item 1A.

Risk Factors

54

Item 2.

Unregistered

Sales of Equity Securities and Use of Proceeds

54

Item 3.

Defaults Upon

Senior Securities

55

Item 4.

Submission of

Matters to a Vote of Security Holders

55

Item 5.

Other

Information

55

Item 6.

Exhibits

55

Signature

56

PART

I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(millions

of dollars, except per common share data)

July 2,

2006

July 3,

2005

July 2,

2006

July 3,

2005

Revenues

11,741

11,452

23,488

23,595

Costs

and expenses:

Cost of sales(a)

1,790

1,762

3,461

3,639

Selling, informational and administrative expenses(a)

3,881

3,766

7,276

7,431

Research and development expenses(a)

1,742

1,830

3,285

3,547

Amortization of intangible assets

823

856

1,648

1,736

Merger-related in-process research and development

charges

513

260

513

262

Restructuring charges and merger-related costs

268

264

567

480

Other (income)/deductions - net

(359)

(198)

(615)

854

Income from continuing operations before provision/(benefit)

for taxes on income and minority interests

3,083

2,912

7,353

5,646

Provision/(benefit) for taxes on income

790

(464)

1,052

2,111

Minority interests

Income from continuing operations

2,290

3,375

6,296

3,531

Discontinued operations:

Income from discontinued operations - net

of tax

108

88

210

191

Gains on sales of discontinued

operations - net of tax

17

--

20

41

Discontinued operations - net of tax

125

88

230

232

Net income

2,415

3,463

6,526

3,763

Earnings

per common share - basic:

Income from continuing operations

0.31

0.46

0.86

0.48

Discontinued operations - net of tax

0.02

0.01

0.03

0.03

Net income

0.33

0.47

0.89

0.51

Earnings

per common share - diluted:

Income from continuing operations

0.31

0.46

0.86

0.48

Discontinued operations - net of tax

0.02

0.01

0.03

0.03

Net income

0.33

0.47

0.89

0.51

Weighted-average shares used to calculate earnings

per common share:

Basic

7,282

7,366

7,298

7,391

Diluted

7,305

7,418

7,330

7,445

Cash

dividends paid per common share

0.24

0.19

0.48

0.38

(a)

Exclusive

of amortization of intangible assets, except as disclosed in Note 12B, Goodwill

and Other Intangible Assets: Other Intangible Assets.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(millions

of dollars)

July 2,

2006*

Dec. 31,

2005**

ASSETS

Current Assets

Cash and cash

equivalents

1,921

2,247

Short-term

investments

12,829

19,979

Accounts

receivable, less allowance for doubtful accounts

9,275

9,103

Short-term

loans

511

510

Inventories

6,392

5,478

Prepaid

expenses and taxes

3,262

2,903

Assets of

discontinued operations and other assets held for sale

6,804

6,659

Total current assets

40,994

46,879

Long-term

investments and loans

2,387

2,497

Property, plant and equipment, less

accumulated depreciation

16,483

16,233

Goodwill

21,057

20,985

Identifiable

intangible assets, less accumulated amortization

26,134

26,244

Other assets,

deferred taxes and deferred charges

4,495

4,860

Total assets

111,550

117,698

LIABILITIES

AND SHAREHOLDERS' EQUITY

Current Liabilities

Short-term

borrowings, including current portion of long-term debt

3,779

11,589

Accounts

payable

1,740

2,073

Dividends

payable

1,757

1,772

Income taxes

payable

4,356

3,618

Accrued

compensation and related items

1,399

1,602

Other current

liabilities

5,655

6,564

Liabilities of

discontinued operations and other liabilities held for sale

1,369

1,237

Total current liabilities

20,055

28,455

Long-term debt

5,450

6,347

Pension benefit

obligations

2,721

2,681

Postretirement

benefit obligations

1,447

1,424

Deferred taxes

10,369

10,392

Other

noncurrent liabilities

3,019

2,635

Total liabilities

43,061

51,934

Shareholders' Equity

Preferred stock

152

169

Common stock

440

439

Additional

paid-in capital

68,217

67,759

Employee

benefit trust, at fair value

(700)

(923)

Treasury stock

(41,755)

(39,767)

Retained

earnings

40,627

37,608

Accumulated

other comprehensive income

1,508

479

Total shareholders' equity

68,489

65,764

Total liabilities and shareholders'

equity

111,550

117,698

* Unaudited.

** Condensed from audited

financial statements.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended

(millions

of dollars)

July 2,

2006

July 3,

2005

Operating Activities:

Net income

6,526

3,763

Adjustments to reconcile net income to net cash

provided by operating activities:

Depreciation and amortization

2,694

2,776

Share-based compensation expense

326

79

Merger-related in-process research and development

charges

513

262

Intangible asset impairments and other associated

non-cash charges

--

1,213

Gains on disposal of investments, products and

product lines

(114)

(53)

Gains on sales of discontinued operations

(31)

(65)

Deferred taxes from continuing operations

(438)

(931)

Other deferred taxes

45

93

Other non-cash adjustments

219

215

Changes in assets and liabilities (net of businesses

acquired and divested)

(636)

(369)

Net

cash provided by operating activities

9,104

6,983

Investing

Activities:

Purchases of property, plant and equipment

(887)

(997)

Purchases of short-term investments

(5,663)

(7,441)

Proceeds from redemptions of short-term investments

13,239

12,570

Purchases of long-term investments

(248)

(560)

Proceeds from sales of long-term investments

47

568

Purchases of other assets

(78)

(99)

Proceeds from sales of other assets

Proceeds from the sales of businesses, products and

product lines

14

101

Acquisitions, net of cash acquired

(1,989)

(255)

Other investing activities

(116)

276

Net

cash provided by investing activities

4,322

4,169

Financing

Activities:

Increase in short-term borrowings, net

938

90

Principal payments on short-term borrowings

(10,583)

(5,800)

Proceeds from issuances of long-term debt

1,054

Principal payments on long-term debt

(2)

(22)

Purchases of common stock

(2,000)

(3,304)

Cash dividends paid

(3,468)

(2,930)

Stock option transactions and other

318

278

Net cash used in financing activities

(13,743)

(11,686)

Effect of exchange-rate changes on cash and cash

equivalents

(9)

Net decrease in cash and cash equivalents

(326)

(532)

Cash and cash equivalents at beginning of period

2,247

1,808

Cash and cash equivalents at end of period

1,921

1,276

Supplemental Cash Flow Information:

Cash paid during the period for:

Income taxes

921

1,296

Interest

414

329

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation

We prepared the condensed consolidated financial statements

following the requirements of the Securities and Exchange Commission (SEC) for

interim reporting. As permitted under those rules, certain footnotes or other

financial information that are normally required by accounting principles

generally accepted in the United States of America (GAAP) can be condensed or

omitted. Balance sheet amounts and operating results for subsidiaries operating

outside the U.S. are as of and for the three-month and six-month periods ended May 28,

2006 and May 29, 2005.

We made certain reclassifications to the 2005 condensed

consolidated financial statements to conform to the 2006 presentation. These

reclassifications are primarily related to discontinued operations (see Note

3, Discontinued Operations) as well as to better reflect jurisdictional

netting of deferred taxes.

Revenues, expenses, assets and liabilities can vary during

each quarter of the year. Therefore, the results and trends in these interim

financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements

included in this document. The financial statements include all normal and

recurring adjustments that are considered necessary for the fair presentation

of our financial position and operating results.

The information included in this Quarterly Report on

Form 10-Q should be read in conjunction with the consolidated financial

statements and accompanying notes included in Pfizer's Annual Report on

Form 10-K for the year ended December 31, 2005.

Note 2. Acquisitions

On May 16, 2006, we completed the acquisition of all of the outstanding

shares of Rinat Neuroscience Corp., a biologics company

with several new central-nervous-system product candidates. In

connection with the acquisition, as part of our preliminary purchase price

allocation, we recorded $478 million, pre-tax, in

Merger-related

in-process research and development charges.

On February 28, 2006, we completed the acquisition of the sanofi-aventis

world-wide rights, including patent rights and production technology, to

manufacture and sell Exubera, an inhaled form of insulin for use in adults with

type 1 and type 2 diabetes, and the insulin-production business and facilities

located in Frankfurt, Germany, previously jointly owned by Pfizer and

sanofi-aventis, for approximately $1.4 billion (including transaction

costs). In connection with the acquisition, as part of our preliminary purchase

price allocation, we recorded an intangible asset for developed technology

rights of approximately $1.0 billion, inventory valued at $218 million

and goodwill of approximately $166 million, all of which have been

allocated to our Human Health segment. The amortization of the developed

technology rights will be primarily included in Cost of Sales. Given

the size and complexity of the acquisition, the fair valuation and allocation

work is still being finalized and is expected to be completed in the third

quarter. To the extent that our estimates need to be adjusted, we will do so. Prior

to the acquisition, in connection with our collaboration agreement with

sanofi-aventis, we recorded a research and development milestone due to us from

sanofi-aventis of approximately $118 million ($71 million, after tax)

in the first quarter of 2006 in Research and development expenses upon

the approval of Exubera in January 2006 by the Food and Drug Administration

(FDA).

Note 3. Discontinued Operations

We evaluate our businesses and

product lines periodically for strategic fit within our operations. As a result

of our evaluation, we decided to sell a number of businesses and product lines,

certain of which qualified for Discontinued operations treatment:

In June 2006,

we entered into an agreement to sell our Consumer Healthcare business for

approximately $16.6 billion in cash. This business comprises

substantially all of our former Consumer Healthcare segment and other associated

amounts, such as purchase-accounting impacts and merger-related costs, and

restructuring and implementation costs related to our Adapting to Scale (AtS)

productivity initiative, previously reported in the Corporate/Other segment. In

addition, certain manufacturing facility assets and liabilities, which were

previously part of our Human Health or Corporate/Other segment, are included

in the planned sale of the Consumer Healthcare business. In connection with the

decision to sell this business, for all periods presented, the operating

results associated with this business that will be discontinued have been

reclassified into Discontinued operations - net of tax in the condensed

consolidated statements of income and the assets and liabilities associated

with this business that will be sold have been reclassified into Assets/Liabilities

of discontinued operations and other assets/liabilities held for sale, as

appropriate, on the condensed consolidated balance sheets. The divestiture of

the Consumer Healthcare business is expected to close in late 2006 and is

subject to customary closing conditions, including receipt of regulatory

approvals.

In the first

quarter of 2005, we sold the second of three European generic pharmaceutical

businesses, which had been included in our Human Health segment, for 70 million

euros (approximately $93 million) and recorded a gain of $57 million

($36 million, net of tax) in Gains on sales of discontinued

operations - net of tax in the condensed consolidated statement of

income. In addition, we recorded an impairment charge of $9 million ($6 million,

net of tax) related to the third European generic business in Income from

discontinued operations - net of tax in the condensed consolidated

statement of income for the six months ended July 3, 2005.

The following amounts, primarily

related to our Consumer Healthcare business, have been segregated from

continuing operations and included in Discontinued operations - net of tax in

the condensed consolidated statements of income:

Three

Months Ended

Six

Months Ended

(in millions)

July 2,

2006

July

3,

2005

July 2,

2006

July

3,

2005

Revenues

1,027

987

1,946

1,951

Pre-tax income

160

134

315

290

Provision for

taxes on income

(52)

(46)

(105)

(99)

Income from

operations of discontinued businesses - net of tax

108

88

210

191

Pre-tax gains on sales of

discontinued businesses

26

--

31

65

Provision for taxes on gains

(9)

--

(11)

(24)

Gains on sales

of discontinued businesses - net of tax

17

--

20

41

Discontinued operations-net of tax

125

88

230

232

The following assets and

liabilities, primarily related to our Consumer Healthcare business, have been

segregated and included in Assets of discontinued operations and other

assets held for sale and Liabilities of discontinued operations and

other liabilities held for sale, as appropriate, in the condensed consolidated

balance sheets:

(in millions)

July 2,

2006

Dec. 31,

2005

Accounts receivable, less allowance

for doubtful accounts

742

661

Inventories

567

561

Prepaid expenses and taxes

81

71

Property, plant and equipment - net

986

1,002

Goodwill

2,756

2,789

Identifiable intangible assets,

less accumulated amortization

1,643

1,557

Other assets, deferred taxes and

deferred charges

29

18

Assets of discontinued operations and

other assets held for sale

6,804

6,659

Current liabilities

610

538

Other

759

699

Liabilities of

discontinued operations and other liabilities held for sale

1,369

1,237

Net cash flows of our discontinued operations from each of

the categories of operating, investing and financing activities were not

significant for the six months ended July 2, 2006 and July 3, 2005.

Note 4. Adoption of New Accounting Standards

On January 1, 2006, we adopted the provisions of Statement

of Financial Accounting Standards (SFAS) No. 123R, Share-Based Payment, as

supplemented by the interpretation provided by SEC Staff Accounting Bulletin

(SAB) No. 107, issued in March 2005. (SFAS 123R replaced SFAS 123, Stock-Based

Compensation, issued in 1995.) We have elected the modified prospective

application transition method of adoption and, as such, prior-period financial

statements have not been restated. Under this method, the fair value of all stock

options granted or modified after adoption must be recognized in the consolidated

statement of income and total compensation cost related to nonvested awards not

yet recognized, determined under the original provisions of SFAS 123, must also

be recognized in the consolidated statement of income.

Prior to January 1, 2006, we accounted for stock options

under Accounting Principle Board Opinion (APB) No. 25, Accounting for Stock

Issued to Employees, an elective accounting policy permitted by SFAS 123.

Under this standard, since the exercise price of our stock options granted is

set equal to the market price on the date of the grant, we did not record any

expense to the condensed consolidated statement of income related to stock

options, unless certain original grant date terms were subsequently modified.

However, as required, we disclosed, in the Notes to Consolidated Financial

Statements, the pro forma expense impact of the stock option grants as if we

had applied the fair-value-based recognition provisions of SFAS 123.

The adoption of SFAS 123R primarily impacted our accounting

for stock options (see Note 14, Share-Based Payments).